Design Module

Design Module

The Design Module contains detailed information about the study design, including study type, allocation methods, intervention models, masking information, primary purpose, enrollment details, and biospecimen information. This module provides essential details about how the clinical trial is structured and conducted.

Design Module path is as follows:

Study -> Protocol Section -> Design Module

Design Module


Ignite Creation Date: 2025-12-24 @ 4:14 PM
Ignite Modification Date: 2025-12-24 @ 4:14 PM
NCT ID: NCT04476966
Study Type: INTERVENTIONAL
Allocation: RANDOMIZED
Primary Purpose: OTHER
Study: NCT04476966
Study Brief: Bioequivalence Study of Mirabegron From Bladogra 25 mg Extended Release Tablets (Multi-Apex for Pharmaceutical Industries, Egypt) Versus Myrbetriq 25 mg Extended Release Tablets (Marketed by Astellas Pharma US, Inc, Product of Japan)
Protocol Section: NCT04476966
Bio Specs (If Any):
Design Masking Infos (If Any):

Design Masking Infos

Design Masking Brief View
None View
Design Observational Models (If Any):
Design Time Perspectives (If Any):
Design Who Masked (If Any):
Enrollment Infos (If Any):

Enrollment Infos

Enrollment Type Enrollment Count View
ACTUAL 29 View
Expanded Access Types (If Any):
Phases (If Any):

Phases

Phase Brief Phase Text View
None PHASE1 View